Last $23.86 USD
Change Today -0.14 / -0.58%
Volume 1.7M
IDIX On Other Exchanges
Symbol
Exchange
IDIX is not on other exchanges.
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

idenix pharmaceuticals inc (IDIX) Snapshot

Open
$24.01
Previous Close
$24.00
Day High
$24.08
Day Low
$23.77
52 Week High
07/1/14 - $24.22
52 Week Low
10/31/13 - $2.93
Market Cap
3.6B
Average Volume 10 Days
1.9M
EPS TTM
$-0.90
Shares Outstanding
150.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IDENIX PHARMACEUTICALS INC (IDIX)

idenix pharmaceuticals inc (IDIX) Related Businessweek News

No Related Businessweek News Found

idenix pharmaceuticals inc (IDIX) Details

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of human viral diseases in the United States and France. Its primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). The company’s HCV discovery program focuses on nucleoside/nucleotide polymerase inhibitors, NS5A inhibitors, protease inhibitors, and non-nucleoside polymerase inhibitors. It is also developing non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency (HIV) virus type-1 and acquired immune deficiency syndrome (AIDS); and products and drug candidates for the treatment of patients with hepatitis B virus (HBV). The company has a collaboration agreement with Janssen Pharmaceuticals, Inc.; Novartis Pharma AG; ViiV Healthcare Company; and GlaxoSmithKline. Idenix Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

84 Employees
Last Reported Date: 02/27/14
Founded in 1998

idenix pharmaceuticals inc (IDIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $546.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $328.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $376.9K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $335.2K
Senior Vice President of Human Resources
Total Annual Compensation: $272.1K
Compensation as of Fiscal Year 2013.

idenix pharmaceuticals inc (IDIX) Key Developments

Idenix Pharmaceuticals, Inc. Announces Positive Data from Hepatitis C Virus Program

Idenix Pharmaceuticals Inc. has announced positive clinical data from the company's program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus, or HCV, infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log10 IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Based on this progress, the Company's goal is to initiate a combination clinical trial of IDX21437 and samatasvir, a pan-genotypic NS5A inhibitor, in mid-2014. In addition, Idenix has selected a follow-on uridine-based nucleotide prodrug, IDX21459, from its ongoing nucleotide discovery program and initiated enrollment for the healthy volunteer portion of a phase I clinical trial. As more all-oral regimens become available to treat hepatitis C, an increased number of patients will be diagnosed and treated. It will be important to have simple, short duration options for the company's patients. These early data for IDX21437 support its potential to be part of future treatment combinations. In January 2014, Idenix initiated the seven-day proof-of-concept portion of a phase I/II clinical trial for IDX21437. The trial completed enrollment of 44 treatment-naive, genotype (GT) 1, 2 or 3 HCV-infected patients. Patients were randomized to receive once-daily doses of placebo, 50 mg, 150 mg, or 300 mg of IDX21437 for seven days. IDX21437 was well-tolerated with no observed pattern of adverse events or laboratory abnormalities. Treatment with IDX21437 exhibited potent pan-genotypic activity in a dose-dependent manner: In GT 1 HCV-infected patients (n=8), the mean maximal viral load reduction was 4.2 log10 IU/mL in the 300 mg arm. The mean maximal viral load reduction of 4.3 log10 IU/mL was achieved in GT 2 and 3 HCV-infected patients in the 300 mg arm (n=10). In April 2014, Idenix initiated enrollment for the healthy volunteer portion of a phase I clinical trial of IDX21459 in Europe. This portion of the study is expected to enroll approximately 50 healthy volunteers and will evaluate once-daily doses of IDX21459 ranging from 10 mg - 300 mg. The proof-of-concept portion of the study is expected to enroll a total of 40 treatment-naive, genotype 1 HCV-infected patients who will receive once-daily doses of placebo, 50 - 300 mg of IDX21459 for seven days. IDX21459 has shown a favorable preclinical profile including potent, pan-genotypic activity and favorable safety with respect to cardiac, mitochondrial and genotoxicity assessments.

Idenix Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Idenix Pharmaceuticals Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the first quarter 2014, the company reported total negative revenues of $3.007 million, compared to total revenues of $0.852 million in the first quarter of 2013. Loss from operations was $34.387 million against $31.023 million a year ago. Loss before income taxes was $34.113 million against $30.752 million a year ago. Net loss was $34.114 million, or $0.24 per basic and diluted share, for the first quarter ended March 31, 2014, compared to a net loss of $30.753 million, or $0.23 per basic and diluted share for the first quarter ended March 31, 2013.

Idenix Pharmaceuticals Inc., Annual General Meeting, Jun 05, 2014

Idenix Pharmaceuticals Inc., Annual General Meeting, Jun 05, 2014., at 09:00 Eastern Daylight. Location: WilmerHale. Agenda: To elect directors for a one-year term; to approve 2014 employee stock purchase plan and the reservation of 2,000,000 shares for future issuance thereunder; to ratify the appointment of its independent registered public accounting firm; to approve an advisory vote on executive compensation; and to transact any other business that may properly come before the meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDIX:US $23.86 USD -0.14

IDIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDIX.
View Industry Companies
 

Industry Analysis

IDIX

Industry Average

Valuation IDIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales NM Not Meaningful
Price/Book 19.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDENIX PHARMACEUTICALS INC, please visit www.idenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.